Product Details
Inlyta
Axitinib5 mg
Tablet
DIN/PIN/NPN
02389649
Manufacturer
Pfizer Canada Inc.
Formulary Listing Date
2023-04-28
Unit Price
102.5387
Amount MOH Pays
102.5387
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
L01EK01
Interchangeable Products
NOLU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Oncology Drugs | Axitinib
For the treatment of advanced renal cell carcinoma (MRCC) in patients who meet the following criteria:
Notes:
Funded Dosing Regimen: 5 mg twice a day. Dose may be adjusted based on individual response and tolerability. Renewal Criteria: Renewals will be considered in patients who have not experienced disease progression or unacceptable toxicity while being treated with axitinib. Approval duration of initials and renewals: 1 year EAP Drug Request Form: |